Characteristics of Leukemias, Lymphomas, and Myelomas

Leukemias, lymphomas, and myelomas are classified as neoplastic proliferative diseases (neoplasms).
- Definition of leukemia: A disease primarily affecting leukocytes located in the blood and bone marrow.
- Definition of lymphoma: A general term for malignancies that originate in the lymphatic system, predominantly affecting lymph nodes.
  - Major types of lymphoma:
    - Hodgkin’s lymphoma
    - Non-Hodgkin’s lymphoma
- Definition of myeloma: A type of cancer affecting plasma cells, where there is an overgrowth forming a mass or tumor primarily in the bone marrow.

Forms of Leukemia

Historical context: Symptoms of leukemia have been documented since Hippocrates's time.
- First recognition: Virchow identified leukemia as a distinct clinical disorder between 1839 and 1845.
  - Naming: Virchow called it leukemia due to the white appearance of the blood in patients exhibiting fever, weakness, and lymphadenopathy.
- Original classification: Virchow initially divided leukemias based on the presence of lymphadenopathy (swelling of lymph nodes).
- Modern classification: Sophisticated systems now exist, including molecular diagnostics for leukemia and lymphoma.

Main Classification Systems

Different Classification Systems:
- French-American-British (FAB) classification:
  - Originally classified leukemias by predominant blood cell type's morphology and cytochemical traits.
  - Divided into three groups based on cell type:
    - Myelogenous
    - Monocytic
    - Lymphocytic
- World Health Organization (WHO) classification:
  - Stratifies neoplasms primarily on lineage:
    - Myeloid
    - Lymphoid
    - Histiocytic/dendritic cell
  - Incorporates morphological data, immunophenotyping, and molecular genetic studies of samples like peripheral blood and bone marrow.

Comparison of Leukemias and Lymphomas

Table 20.1: Comparative Features
- Leukemia:
  - Characterized by the overproduction of various types of immature or mature leukocytes in the bone marrow and/or peripheral blood, predominantly involving myelogenous or lymphocytic cells.
  - Malignant cells can cross the blood-brain barrier.
- Lymphoma:
  - Represents solid malignant tumors of the lymph nodes, primarily involving lymphocytes.
  - Reed-Sternberg cells serve as a diagnostic indicator for Hodgkin's-type lymphoma.
  - Malignant cells are primarily confined to lymphatic organs but may spill into the bloodstream.
- Myeloma:
  - Involves overproduction of plasma cells in the bone marrow, resulting in abnormal protein production.
  - Plasma cells form localized masses or tumors in the bone marrow.

Clinical Symptoms and Classification of Leukemia

Acute vs. Chronic Leukemia:
- Clinical symptoms, cell maturity, and total leukocyte count determine classification:
  - Acute leukemias:
    - Symptoms are short-term.
    - Presence of many immature cell forms in the bone marrow/peripheral blood.
    - Total leukocyte count is markedly elevated.
  - Chronic leukemias:
    - Symptoms last longer.
    - Predominance of mature cell forms in blood/bone marrow.
    - Total leukocyte counts can vastly vary, from very high to below normal.
- Survival prognosis:
  - Untreated acute forms have a survival prognosis ranging from mere weeks to several months.
  - Untreated chronic forms may allow survival ranging from months to many years after diagnosis.

Prognosis and Treatment Considerations

Outcome of Untreated Forms:
- Both untreated leukemias and lymphomas ultimately lead to fatality.
Advancements in Treatment:
- Modern therapeutic agents are more effective in targeting malignant cells while reducing toxicity to normal cells, significantly enhancing patient longevity across various leukemia and lymphoma forms.
- Recent advancements include drugs aimed at molecular targets, particularly effective in chronic myelogenous leukemia.

Factors Related to Leukemia Occurrence

Nature of Leukemia:
- Leukemia is a clonal disease arising from the malignant transformation of hematopoietic progenitor cells.
- The transformation is likely driven by mutations and altered gene expression.
- Production of leukemic stem cells enables proliferation and the formation of dominant cell clones that overwhelm normal hematopoiesis in the bone marrow.

Contributing Factors:

Genetic and immunological influences
Occupational factors, particularly exposure to carcinogens
Environmental influences, such as radiation
Chemical and drug exposures
Genetic abnormalities and associated changes
Viral agents
Secondary causes linked to pre-existing conditions

Genetic and Immunologic Factors in Leukemia

Significance of Mutations:
- Mutations, either in single genes or larger chromosomal changes, frequently arise in leukemia cases.
  - Common chromosomal changes include:
    - Translocations: Most prevalent type of DNA alteration leading to leukemia, involving segments of one chromosome moving to another.
    - Deletions: Loss of chromosome segments, which may remove critical growth-regulating genes (e.g., tumor suppressor genes).
    - Inversions: Inversion of chromosome segments, potentially disrupting gene function.
    - Additions: Gain of extra chromosome segments or entire chromosomes, leading to duplications of oncogenes.

Oncogenes and Tumor Suppressor Genes

Oncogenes:
- Mutation of a single oncogene is insufficient alone to trigger full cancer development.
- Malignant cell proliferation is influenced by oncogenes, which may change how cellular growth is regulated.
Protooncogenes:
- Serve as key growth regulators in normal cells; no established link exists between them and cancer cause.
Tumor-Suppressor Genes:
- Regulate cell proliferation; their inactivation can lead to uncontrolled cellular growth.
- Also known as antioncogenes, these genes play a crucial role in cancer persistence and progression.
Diffusible factors:
- These factors, such as β-Interferon and tumor growth factors, influence cell differentiation in neighboring cells.

Environmental and Occupational Exposure Risks

Occupational Risks:
- Ionizing radiation poses a known risk factor for leukemia, significantly affecting radiologists historically.
- Associated primarily with acute and chronic myelogenous leukemia.
Environmental Risks:
- Risk from low-level radiation (e.g., x-rays, CT scans) remains inadequately defined.
- High radiation levels are strong risk factors for acute leukemia; studies of atomic bomb survivors reflect this increased risk visible within 6-8 years.
Chemical Exposure:
- Certain chemicals, notably benzene, are correlated with increased leukemia incidence.
- Benzene exposure is also common in cigarette smoke and various household products, posing elevated risks particularly for acute myelogenous leukemia.

Genetic Abnormalities and Associations in Leukemia

Cytogenetic anomalies are increasingly linked to several leukemia forms.
Specific genetic abnormality trends coincide with mutations in stem cells, which can also relate to increased lymphoma risk alongside genetic predispositions or deficiencies in immune regulation.

Chromosomal Translocations:

Philadelphia Chromosome:
- The most frequent translocation in adult acute lymphoblastic leukemia (ALL), corresponding to a swap of DNA segments between chromosomes 9 and 22 (denoted as t(9;22)), found in 25-30% of ALL cases.
Other translocations include t(4;11) and t(8;14), along with other changes like deletions and inversions, albeit these are less common.

Viral Agents and Leukemia Links

Certain viral infections are implicated in leukemia development:
- Epstein-Barr virus (EBV) links are notably observed with Burkitt’s lymphoma and acute lymphocytic leukemia.
- Human T-cell lymphoma/leukemia virus-1 (HTLV-1) is associated with a rare T-cell acute lymphocytic leukemia, predominantly found in Japan and the Caribbean.

Secondary Leukemias:

Possible development of secondary acute myeloid leukemia (AML) occurs in patients with:
- Pre-existing hematologic disorders (e.g., congenital neutropenia).
- Inherited syndromes (e.g., Fanconi’s anemia).
- Myelodysplastic syndrome spanning more than three months.
- Patients treated with leukemogenic agents for an unrelated neoplasm.

Demographic Distribution of Leukemias, Lymphomas, and Myelomas

Key Factors Influencing Occurrence:
- Ethnic background
- Racial demographics
- Age groups
- Gender ratios.

Ethnic Origin and Race:

Overall leukemia rates vary worldwide:
- Highest incidences are reported in Scandinavian countries and Israel, with the lowest in Japan and Chile.
- Among adult Whites, chronic lymphocytic leukemia accounts for over 20% of new cases, contrasting with its rarity in Asian populations.
- Pediatric ALL shows a higher prevalence in White children compared to African American and Asian American counterparts.
- Myeloma incidence is approximately double in African Americans compared to Caucasians.

Age Factors:

Leukemia in Children:
- Leading cause of cancer diagnosis and mortality rates in children 0 to 19 years.
- Highest incidence found in children aged 1 to 4 years; the highest mortality rate amongst those aged 15-19 years.

Gender Distribution:

Gender Prevalence Trends:
- Leukemia diagnosis prevalence is generally higher in American males than females across racial and age groups, with the exception of children under 18 months.
- ALL has a slight gender prevalence in boys over girls, while AML rates are equal across genders.
- Significant gender disparity noted in chronic lymphocytic leukemia (CLL) with a male:female ratio of approximately 2:1 for adults.

Leukemia Vaccines and Treatment Advancements

Vaccination and Remission:
- High-dose chemotherapy can lead to clinically complete remission in most leukemia cases but with frequent relapse tendencies.
- Effective leukemia treatment necessitates eradicating minimal residual disease (MRD).
  - Cancer vaccine therapy shows potential for controlling or eradicating MRD and may serve as a viable alternative responsive treatment to conventional chemotherapy.